K-ras as a target for lung cancer therapy

Journal of Thoracic Oncology

Volumn 3, Issue 6 SUPPL 2, 2008, Pages

  Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

K ras; Mitogen activated protein kinase; NSCLC; Raf kinase

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; B RAF KINASE; BEVACIZUMAB; GEFITINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLACEBO; RAF PROTEIN; SORAFENIB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLURRED VISION; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

EID: 44649143914     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318174dbf9     Document Type: Article

References (21)

1. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074.
2. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLos Med 2005;2:e17.
3. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993;62:851-891.
4. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
5. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-1043.
6. Adjei AA. Farnesyl transferase inhibitors. Cancer Chemother Biol Response Modif 2003;21:127-144.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
8. Levy AP, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res 2006;47:213-214 (abstract and oral presentation).
9. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-6869.
10. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480.
11. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861.
12. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694.
13. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
14. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2005;3:226.
15. Adjei AA, Molina JR, Marks R, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Clin Cancer Res 2007;13:2684-2691.
16. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-4462.
17. Lorusso P, Krishnamurthi S, Rinehart JR, et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol (Meeting Abstr) 2005;23:3011.
18. Menon SS, Whitfield LR, Sadis S, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol (Meeting Abstr). 2005;23:3066.
19. Wang D, Boerner SA, Winkler JD, Lorusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-1255.
20. Pfizer Pipeline. Available at: http://www.pfizer.com/research/pipeline. jsp. Accessed October 15, 2007.
21. Adjei AA, Cohen RB, Franklin WA, Molina J. Phase IB and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies. AACR-EORTC-NCI Molecular Targets Meeting, November 2006.